LTGO Latigo Biotherapeutics, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Latigo Biotherapeutics, Inc. reported revenue of n/a, net income of −$25.8M and diluted EPS of −$27.59.
LTGO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.8M, EPS −$27.59
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.0M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$25.8M, EPS −$36.52
- Quarter ended Mar 31, 2025: revenue n/a, net income −$21.0M, EPS n/a
LTGO balance sheet
- Jun 30, 2026: cash $55.0M, total assets $64.8M, total liabilities $52.3M, shareholders' equity −$276M
- Dec 31, 2025: cash $69.4M, total assets $75.5M, total liabilities $18.6M, shareholders' equity −$232M